Publication number: 20100029605
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
Type:
Application
Filed:
September 24, 2007
Publication date:
February 4, 2010
Applicants:
Novartis AG
Inventors:
Pamela Albaugh, Gregory S. Chopiuk, Qiang Ding, Shenlin Huang, Zuosheng Liu, Shifeng Pan, Pingda Ren, Xia Wang, Xing Wang, yongping Xie, Chengzhi Zhang, Qiong Zhang, Guobao Zhang, Daniel Poon, Paul Renhowe, Martin Sendzik
